当前位置: 首页 > 期刊 > 《中国现代医生》 > 2012年第16期
编号:12240851
解脲脲原体喹诺酮类药物耐药机制的研究(3)
http://www.100md.com 2012年6月5日 《中国现代医生》 2012年第16期
     [参考文献]

    [1] Hartmann M. Genital mycoplasmas[J]. J Dtsch Dermatol Ges,2009,7(4):371-377.

    [2] Zhang W,Wu Y,Yin W,et al. Study of isolation of fluoroquinolone-resistant Ureaplasma urealyticum and identification of mutant sites[J]. Chin Med J,2002,115(10):1573-1575.

    [3] Bébéar CM,Renaudin H,Charron A,et al. DNA gyrase and topoisomerase IV mutations in clinical isolates of Ureaplasma spp. and mycoplasma hominis resistant to fluoroquinolones[J]. Antimicrobial Agents and Chemotherapy,2003,47(10):3323-3325.

    [4] Xie X,Zhang J. Trends in the rates of resistance of Ureaplasma urealyticum to antibiotics and identification of the mutation site in the quinolone resistance-determining region in Chinese patients[J]. FEMS Microbiol Lett,2006,259(2):181-186.

    [5] Beeton ML,Chalker VJ,Kotecha S,et al. Comparison of full gyrA, gyrB, parC and parE gene sequences between all Ureaplasma parvum and Ureaplasma urealyticum serovars to separate true fluoroquinolone antibiotic resistance mutations from non-resistance polymorphism[J]. J Antimicrob Chemother,2009, 64(3):529-538.

    [6] Chen FJ,Lo HJ. Molecular mechanisms of fluoroquinolone resistance[J]. J Microbiol Immunol Infect,2003,36(1):1-9.

    (收稿日期:2012-03-22), 百拇医药(张一沙 吴颖 范兴丽 蒋锦琴 孙爱华)
上一页1 2 3